News Lilly forges a $415m ALS alliance with UK biotech Alchemab Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients.
News Denali's ALS programme suffers another setback Prospects for Denali Therapeutics' experimental medicine for amyotrophic lateral sclerosis have taken another tumble.
News Four more drugs in keenly watched ALS trial miss the mark ALS candidates from Biohaven, Prilenia, Clene, and UCB were unable to slow disease progression in the study, but two showed signs of efficacy.
News Denali slides after ALS drug flunks clinical test Another clinical trial setback disappoints the ALS patient community, this time involving Denali's eIF2B agonist DNL343.
News Neuralink unveils trial linking brain implant to robotic arm Neuralink has been given regulatory approval to start a new trial of its brain implant to see if it can be used to control a robotic arm
News NeuroSense says ALS drug extends survival NeuroSense Therapeutics is currently facing de-listing from the Nasdaq, so encouraging data from a phase 2b trial of its PrimeC drug candidate for amyotrophic lateral sclerosis (ALS) comes
News DMD gene therapy Elevidys linked to new liver failure case Another death from liver failure has been seen with Roche and Sarepta's Duchenne muscular dystrophy therapy Elevidys, prompting a pause on treatment.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face